查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1559552

全球內分泌檢測市場

Endocrine Testing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 168 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2030年全球內分泌檢測市場預計將達169億美元

全球內分泌檢測市場預計 2023 年為 120 億美元，預計到 2030 年將達到 169 億美元，2023 年至 2030 年複合年成長率為 5.0%。串聯式質譜質譜技術是本報告分析的細分市場之一，預計複合年成長率為 6.2%，到分析期結束時將達到 53 億美元。分析期內，免疫測量技術領域的複合年成長率預計為5.0%。

美國市場預估32億美元，中國預估複合年增率7.7%

預計2023年美國內分泌檢測市場規模將達32億美元。中國作為全球第二大經濟體，預計2030年市場規模將達到38億美元，2023年至2030年的分析期間複合年成長率為7.7%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 2.5% 和 4.7%。在歐洲，德國的複合年成長率預計為 2.9%。

全球內分泌檢測市場—主要趨勢和促進因素總結

內分泌檢測將如何徹底改變醫療保健和疾病管理？

內分泌檢測透過提供對人體荷爾蒙系統功能的重要洞察，正在徹底改變醫療保健和疾病管理，荷爾蒙系統在調節新陳代謝、生長、繁殖和整體健康方面發揮著重要作用。此類測試透過分析血液、尿液和唾液樣本來測量荷爾蒙水平，從而幫助診斷、監測和管理各種內分泌疾病，包括糖尿病、甲狀腺疾病、腎上腺功能不全和生殖健康問題。準確檢測和監測荷爾蒙失衡對於有效治療至關重要。檢測技術的進步使內分泌檢測變得更加準確、方便和全面，使醫療保健提供者能夠更早地診斷病情、更有效地制定治療方案並更準確地監測進展情況，現在您可以了。隨著我們對內分泌系統了解的加深及其與肥胖、心血管疾病和骨質疏鬆症等慢性疾病的關係變得更加清晰，內分泌檢測作為預防和個人化醫療的基石越來越受到關注。

哪些創新將改善內分泌檢測的功能？

內分泌檢測領域的創新正在透過診斷技術、自動化和個人化醫療的進步來增強其能力。最重要的進步之一是引入了靈敏且特異性的測定方法，例如免疫測量和質譜法。這些先進的檢測方法減少了假陽性和假陰性的可能性，並提供更可靠的診斷資訊。內分泌檢測實驗室的自動化也是一項重要的創新，能夠以最少的人為干預實現樣本的高通量處理。這不僅加快了檢查過程，還減少了人為錯誤的可能性，並確保結果一致和準確。此外，內分泌檢測與個人化醫療方法的結合正在改變荷爾蒙相關疾病的治療方式。透過將荷爾蒙水平資料與遺傳、生活方式和環境因素相結合，醫療保健提供者可以製定量身定做的治療計劃，以滿足每位患者的獨特需求，改善治療結果，並降低併發症的風險。此外，針對特定激素（例如皮質醇和甲狀腺刺激素（TSH））的家庭檢測套組的開發使內分泌測試變得更容易為公眾所接受，使個人能夠方便、頻繁地監測自己的激素水平。這些創新使內分泌檢測更加準確、有效率、以患者為中心，推動內分泌疾病診斷和管理的改善。

內分泌測試如何影響疾病管理和病患結果？

內分泌檢測透過實現早期診斷、有針對性的治療和持續監測荷爾蒙相關疾病，對疾病管理和患者結果產生重大影響。及早發現甲狀腺功能亢進、糖尿病和腎上腺功能不全等內分泌疾病可以及時干預，防止疾病進展並降低嚴重併發症的風險。例如，透過內分泌檢測及早發現甲狀腺功能障礙可以預防因甲狀腺疾病未經治療而導致的併發症，例如心臟病和心理健康問題。在糖尿病等慢性疾病的治療中，定期進行內分泌檢測對於監測血糖值並根據需要調整治療計劃至關重要，以保持最佳的血糖控制並預防神經病變等併發症。準確測量和監測荷爾蒙水平的能力也使醫療保健提供者能夠微調治療，確保精確的藥物劑量並根據個人的荷爾蒙狀況量身定做治療。這種個人化的方法不僅提高了治療效果，也提高了患者的依從性和滿意度。透過提供關鍵資訊來指導內分泌疾病的管理，內分泌檢測在改善患者的治療結果和生活品質方面發揮關鍵作用。

推動內分泌檢測市場成長的趨勢是什麼？

多種趨勢正在推動內分泌檢測市場的成長，包括內分泌疾病盛行率的上升、診斷技術的進步以及對預防性醫療保健日益成長的興趣。全球糖尿病、甲狀腺疾病和METABOLIC INC.症候群等疾病的增加，需要持續監測和管理，推動了對準確、全面的內分泌檢測的需求。人口老化也促進了這一成長，因為老年人更容易受到荷爾蒙失衡和相關疾病的影響。次世代定序和免疫檢測檢測等診斷技術的進步使內分泌檢測更加準確、高效和廣泛使用，進一步推動了市場擴張。對預防保健的日益重視也是一個重要因素。這是因為早期發現和管理荷爾蒙失衡對於預防慢性病的發作和改善長期健康結果至關重要。此外，內分泌測試與數位健康平台和遠端醫療的整合正在擴大這些測試的使用範圍，並實現遠端監控和諮詢，特別是對於服務不足和農村地區的患者來說是有益的。此外，透過將內分泌檢測與遺傳和生活方式資料相結合來客製化治療的個人化醫療的發展，正在增加內分泌檢測作為個人化醫療工具的吸引力。這些趨勢凸顯了內分泌檢測在現代醫療保健中日益重要，內分泌檢測已成為疾病預防、管理和個人化治療策略的核心組成部分。

受訪企業範例（總合31 家知名企業）

  • Agilent Technologies, Inc.
  • Apollo Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Dartmouth-Hitchcock
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG
  • HCA Healthcare UK
  • Holston Medical Group
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics, Inc.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP11785

Global Endocrine Testing Market to Reach US$16.9 Billion by 2030

The global market for Endocrine Testing estimated at US$12.0 Billion in the year 2023, is expected to reach US$16.9 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Tandem Mass Spectrometry Technology, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Immunoassay Technology segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.2 Billion While China is Forecast to Grow at 7.7% CAGR

The Endocrine Testing market in the U.S. is estimated at US$3.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Endocrine Testing Market - Key Trends and Drivers Summarized

How Is Endocrine Testing Revolutionizing Healthcare and Disease Management?

Endocrine testing is revolutionizing healthcare and disease management by providing critical insights into the functioning of the body’s hormonal system, which plays a vital role in regulating metabolism, growth, reproduction, and overall well-being. This type of testing involves analyzing blood, urine, or saliva samples to measure hormone levels, which can help diagnose, monitor, and manage various endocrine disorders, such as diabetes, thyroid diseases, adrenal insufficiencies, and reproductive health issues. The accurate detection and monitoring of hormone imbalances are essential for effective treatment, as even small deviations from normal levels can significantly impact a person’s health. With advancements in testing technologies, endocrine testing has become more precise, accessible, and comprehensive, allowing healthcare providers to diagnose conditions earlier, tailor treatments more effectively, and monitor progress with greater accuracy. As the understanding of the endocrine system deepens and its link to chronic diseases like obesity, cardiovascular diseases, and osteoporosis becomes clearer, endocrine testing is increasingly seen as a cornerstone of preventive and personalized medicine.

What Innovations Are Enhancing the Functionality of Endocrine Testing?

Innovations in endocrine testing are enhancing its functionality through advancements in diagnostic technologies, automation, and personalized medicine. One of the most significant developments is the introduction of highly sensitive and specific assays, such as immunoassays and mass spectrometry, which allow for the accurate quantification of even minute hormone levels in the body. These advanced assays reduce the likelihood of false positives and negatives, providing more reliable diagnostic information. Automation in endocrine testing labs is another key innovation, enabling high-throughput processing of samples with minimal human intervention. This not only speeds up the testing process but also reduces the potential for human error, ensuring consistent and accurate results. Additionally, the integration of endocrine testing with personalized medicine approaches is transforming the way hormone-related conditions are managed. By combining hormone level data with genetic, lifestyle, and environmental factors, healthcare providers can create tailored treatment plans that address the unique needs of each patient, improving outcomes and reducing the risk of complications. Furthermore, the development of at-home testing kits for certain hormones, such as cortisol or thyroid-stimulating hormone (TSH), is making endocrine testing more accessible to the general public, allowing individuals to monitor their hormone levels conveniently and frequently. These innovations are making endocrine testing more precise, efficient, and patient-centered, driving improvements in the diagnosis and management of endocrine disorders.

How Does Endocrine Testing Impact Disease Management and Patient Outcomes?

Endocrine testing has a profound impact on disease management and patient outcomes by enabling early diagnosis, targeted treatment, and ongoing monitoring of hormone-related conditions. Early detection of endocrine disorders, such as hyperthyroidism, diabetes, or adrenal insufficiency, allows for timely intervention, which can prevent the progression of the disease and reduce the risk of severe complications. For example, identifying thyroid dysfunction early through endocrine testing can prevent complications like heart disease or mental health issues that may arise from untreated thyroid disorders. In managing chronic conditions like diabetes, regular endocrine testing is essential for monitoring blood glucose levels and adjusting treatment plans as needed, helping to maintain optimal blood sugar control and prevent complications such as neuropathy or cardiovascular disease. The ability to measure and monitor hormone levels accurately also allows healthcare providers to fine-tune treatments, ensuring that medications are dosed correctly and that therapies are tailored to the individual’s hormonal profile. This personalized approach not only improves the effectiveness of treatment but also enhances patient compliance and satisfaction, as treatments are more likely to align with the patient’s specific needs and lifestyle. By providing critical information that guides the management of endocrine disorders, endocrine testing plays a vital role in improving patient outcomes and quality of life.

What Trends Are Driving Growth in the Endocrine Testing Market?

Several trends are driving growth in the endocrine testing market, including the rising prevalence of endocrine disorders, advancements in diagnostic technologies, and the increasing focus on preventive healthcare. The global rise in conditions such as diabetes, thyroid disorders, and metabolic syndromes is fueling demand for accurate and comprehensive endocrine testing, as these conditions require ongoing monitoring and management. The aging population is also contributing to this growth, as older adults are more susceptible to hormone imbalances and related diseases. Advancements in diagnostic technologies, such as next-generation sequencing and advanced immunoassays, are making endocrine testing more accurate, efficient, and widely available, further driving market expansion. The growing emphasis on preventive healthcare is another key factor, as early detection and management of hormone imbalances are critical in preventing the onset of chronic diseases and improving long-term health outcomes. Additionally, the integration of endocrine testing with digital health platforms and telemedicine is expanding access to these tests, allowing for remote monitoring and consultation, which is particularly beneficial for patients in underserved or rural areas. The development of personalized medicine approaches, which combine endocrine testing with genetic and lifestyle data to tailor treatments, is also enhancing the appeal of endocrine testing as a tool for individualized care. These trends highlight the increasing importance of endocrine testing in modern healthcare, as it becomes a central component of disease prevention, management, and personalized treatment strategies.

Select Competitors (Total 31 Featured) -

  • Agilent Technologies, Inc.
  • Apollo Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Dartmouth-Hitchcock
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG
  • HCA Healthcare UK
  • Holston Medical Group
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Endocrine Testing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Global Prevalence of Endocrine Disorders Driving Demand for Testing
    • Technological Advancements in Diagnostic Tests Enhancing Accuracy and Speed
    • Integration of Telehealth and Remote Testing Options Expanding Accessibility
    • Impact of Lifestyle Diseases on the Growing Need for Endocrine Testing
    • Developments in Biomarker Discovery and Its Application in Endocrine Disorders
    • Future Outlook: AI Integration in Diagnostic Workflows for Endocrine Disorders
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Insulin Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Insulin Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Insulin Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Follicle Stimulating Hormone (FSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Follicle Stimulating Hormone (FSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Follicle Stimulating Hormone (FSH) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Thyroid Stimulating Hormone (TSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Thyroid Stimulating Hormone (TSH) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Thyroid Stimulating Hormone (TSH) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Estradiol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Estradiol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Estradiol by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Tandem Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Immunoassay Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Clinical Chemistry Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Clinical Chemistry Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Clinical Chemistry Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Monoclonal & Polyclonal Antibody Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Monoclonal & Polyclonal Antibody Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Monoclonal & Polyclonal Antibody Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Sensors Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Sensors Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Sensors Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 33: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 34: World Endocrine Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Endocrine Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • JAPAN
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • CHINA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • EUROPE
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Endocrine Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 71: France Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: France 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • GERMANY
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Germany 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Italy 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 89: UK Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 92: UK Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: UK 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Spain 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Spain 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Russia 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Russia 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Europe 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Europe 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Endocrine Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Asia-Pacific 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Australia 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Australia 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • INDIA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 128: India Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: India 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 131: India Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: India 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: South Korea 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: South Korea 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Endocrine Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Latin America 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Argentina 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Argentina 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Brazil 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Brazil 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Mexico 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Mexico 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Rest of Latin America 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Rest of Latin America 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Endocrine Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Middle East 16-Year Perspective for Endocrine Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Iran 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Iran 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Israel 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Israel 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Saudi Arabia 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Saudi Arabia 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: UAE 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: UAE 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Rest of Middle East 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Rest of Middle East 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030
  • AFRICA
    • Endocrine Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Endocrine Testing by Test Type - Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Africa 16-Year Perspective for Endocrine Testing by Test Type - Percentage Breakdown of Value Sales for Thyroid Stimulating Hormone (TSH) Testing, Insulin Testing, Estradiol, Follicle Stimulating Hormone (FSH) Testing and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Endocrine Testing by Technology - Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Africa 16-Year Perspective for Endocrine Testing by Technology - Percentage Breakdown of Value Sales for Tandem Mass Spectrometry, Immunoassay Technology, Clinical Chemistry Technology, Monoclonal & Polyclonal Antibody Technology, Sensors Technology and Other Technologies for the Years 2014, 2024 & 2030

IV. COMPETITION